nspr stock: NSPR (InspireMD, Inc.) Overview

This article explains nspr stock — the Nasdaq-listed ticker for InspireMD, Inc. — covering the company, its MicroNet stent technology, regulatory and clinical milestones, financial and market data,...

2024-07-11 00:58:00

By Crypto Linguist

Article rating

4.3

109 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NSPR (InspireMD, Inc.)

nspr stock refers to the publicly traded equity of InspireMD, Inc., listed on the Nasdaq under the ticker NSPR. This article explains what nspr stock represents, summarizes InspireMD's business and MicroNet stent technology, and covers corporate history, products, market and financial information, major risks, and recent developments investors and health‑care observers commonly follow.

This guide is factual and neutral, not investment advice. It highlights authoritative sources where available and notes dates for reported metrics so readers can verify current values independently.

Company overview

InspireMD, Inc. is a medical‑device company focused on developing and commercializing MicroNet® mesh‑based stent platforms designed to reduce periprocedural embolic events during vascular stenting procedures. The company’s product family includes CGuard®, CGuard Prime, and technologies derived from the MGuard platform. InspireMD was founded in the 2000s, is headquartered in Israel with U.S. commercial and regulatory activities, and targets interventional cardiology and vascular surgery markets.

nspr stock represents ownership in InspireMD and trades on the Nasdaq. The company’s stated mission centers on delivering embolic‑protection solutions intended to improve outcomes in carotid artery stenting and related interventions.

History

Early development and technology origins

InspireMD’s core technology, the MicroNet coated or integrated mesh, evolved from earlier efforts to combine stenting with embolic protection. The MicroNet concept integrates a fine mesh into the stent design to trap plaque debris released during stent deployment and ballooning, aiming to reduce the risk of stroke from distal embolization.

Initial R&D focused on optimizing mesh porosity, stent deliverability, and clinical performance in carotid and peripheral vascular anatomies. Early iterations drew on experience from predecessor products such as MGuard and related mesh‑covered systems.

Regulatory and clinical milestones

InspireMD has pursued a mix of clinical studies, CE Mark approvals for European markets, and regulatory submissions for broader approvals. Notable milestone types include:

CE Mark and European commercialization steps for CGuard variants.
Multi‑center clinical trials and registries assessing embolic protection and stroke rates in carotid artery stenting patients.
Regulatory filings and pre‑market submissions in the U.S., with public disclosures about interactions with regulators when applicable.

As of 2026-01-27, according to InspireMD press materials and market data aggregators, the company has emphasized clinical evidence from registries and published studies supporting reduced embolic signals and some clinical event reductions with MicroNet‑equipped stents.

The company’s public listing and capital raises have supported R&D, regulatory work, and limited commercial rollouts. Over time, InspireMD has undergone management and operational changes typical for small medical‑device firms pursuing international market entry.

Products and technology

The main product family centers on MicroNet‑enabled stents designed primarily for carotid artery stenting (CAS) and selected peripheral applications.

CGuard EPS and CGuard Prime: CGuard is a carotid‑specific stent system that integrates a MicroNet barrier designed to retain plaque particles and minimize emboli during the CAS procedure. CGuard Prime represents later design iterations with improvements in deliverability and deployment mechanics.
MGuard derivatives: Earlier MGuard platform concepts informed MicroNet design choices. These products emphasize embolic protection through mesh containment.

Clinical rationale: during carotid stenting, manipulation of an atherosclerotic plaque can dislodge debris. Embolic particles that reach the brain can cause strokes or transient ischemic attacks. MicroNet‑based stents aim to reduce that risk by capturing debris against the vessel wall while maintaining blood flow through mesh pores.

Key intended users are interventional cardiologists, vascular surgeons, and interventional radiologists performing carotid interventions in hospital catheterization laboratories and hybrid operating rooms.

Business model and markets

InspireMD generates revenue primarily through device sales of stents and ancillary delivery systems. Its commercial strategy has focused on:

Selling through distribution partners and direct commercial teams in select regions.
Building clinical evidence and physician adoption through registry data, presentations at conferences, and peer‑reviewed publications.
Pursuing additional regulatory clearances in target markets to expand commercial reach.

Primary end markets are hospitals and health systems with active vascular intervention programs. Geographic emphasis historically includes Europe (where CE Mark pathways are common), select international markets, and efforts to enter or expand in the U.S. market when regulatory pathways permit.

Financial information

As of 2026-01-27, according to public filings and market data aggregators (company investor presentations, Yahoo Finance, Morningstar):

Revenue trend: InspireMD’s revenue historically reflects early commercial traction and limited scale typical for a small medical‑device developer. Revenue can be lumpy due to order timing, distributor arrangements, and the cadence of product launches.
Profitability: The company has generally reported net losses as it invests in clinical development, regulatory work, and commercialization. Net income (loss), R&D spend, and SG&A vary quarter to quarter.
Cash position and financings: InspireMD has periodically raised capital through equity offerings, private placements, or other financings to fund operations and regulatory programs. Cash runway and cash burn are important KPIs for small med‑tech companies.

Investors typically monitor revenue growth, gross margin trends, operating cash burn, and progress on regulatory milestones that could materially affect future sales. For exact, up‑to‑date figures such as trailing twelve‑month revenue, net loss, or cash on hand, consult InspireMD’s most recent SEC filings and company investor relations releases.

Stock market information

Listing: nspr stock trades on the Nasdaq under the symbol NSPR.
Market classification: NSPR is commonly categorized as a small‑cap or micro‑cap equity given its modest market capitalization and shares outstanding relative to large‑cap peers.

As of 2026-01-27, according to Yahoo Finance and CNBC data summaries, nspr stock had a market capitalization in the low tens of millions (approximate and subject to market movement). Daily trading volume can vary widely; investors should check real‑time quote feeds for current liquidity and bid/ask spreads.

Historical price performance

nspr stock has displayed multi‑year volatility common to small medical‑device issuers. Price movements typically reflect clinical data releases, regulatory decisions, financing announcements, and shifts in broader market sentiment toward small‑cap health‑care stocks.

Historical patterns include periods of material rallies following positive clinical or regulatory news and declines tied to dilution risk from financing or slower commercial uptake. For precise 52‑week highs/lows and past performance charts, market data services such as Yahoo Finance and Macrotrends provide historical price series and interactive charts.

Trading characteristics

nspr stock often shows lower average daily volume compared with large‑cap equities, which can increase intraday volatility and widen bid/ask spreads. The ticker is amenable to both regular market hours and after‑hours trading activity on Nasdaq; however, liquidity may be thinner outside core trading sessions.

Investors tracking nspr stock commonly monitor average volume, recent block trades, insider transactions, and institutional filings to gauge supply/demand dynamics.

Valuation and analyst coverage

Valuation metrics: Many standard ratios (P/E) are not meaningful for companies with persistent net losses. Alternative valuation metrics used by analysts include Price/Sales and enterprise value relative to revenue or pipeline milestones.
Analyst coverage: Coverage for nspr stock tends to be sparse compared with larger med‑tech peers. Where coverage exists, analyst commentary typically focuses on commercial ramp potential, regulatory risk, and the weight of clinical evidence supporting reduced embolic events.

Typical analyst considerations include the size of addressable carotid stenting markets, reimbursement dynamics, competitive device offerings, and the likelihood of broader regulatory approvals in major markets.

Major shareholders and insider ownership

Institutional ownership in nspr stock can fluctuate. Major shareholders may include healthcare‑focused funds, small institutional investors, and insider holdings such as executive and director ownership. Insider transactions (purchases or sales) are disclosed in filings and can be material for small‑cap stocks.

As with any public company, check the most recent Form 4, 13D/G filings, and quarterly ownership disclosures for up‑to‑date shareholder composition.

Corporate governance and management

Key executives typically include the CEO, CFO, and heads of clinical and commercial operations. Board composition for small med‑tech firms often blends clinical, regulatory, and financial expertise to guide product development and market entry.

Management changes, strategic hires, or board transitions are frequently disclosed in company press releases. Investors following nspr stock often weigh leadership experience in device commercialization when assessing execution risk.

Recent developments and news

To keep timing clear, examples below reference source and date where reported.

As of 2026-01-27, according to Yahoo Finance and company press releases, InspireMD has continued to report incremental commercial orders and participation in clinical symposia showcasing MicroNet data.
As of 2025 (company statements and market‑news aggregation), InspireMD announced expanded distribution agreements in select territories to support CGuard adoption.
Clinical publications and conference presentations in recent years have reported imaging and clinical registry results suggesting reduced embolic signals with MicroNet‑equipped stents; these items are cited in investor materials (dates and conference names are indicated in specific company releases).
Financing activity: Over the past several years, InspireMD executed equity financings and capital raises to support operations and regulatory efforts. Specific transaction dates and terms are available in SEC filings and press releases.

When tracking nspr stock, watch for upcoming clinical readouts, regulatory decisions, product launches, and reported quarterly financials — each can materially influence share price and trading volume.

Risks

Investors and observers should consider principal business and investment risks associated with nspr stock:

Regulatory risk: Approval pathways and regulatory decisions (CE Mark maintenance, potential FDA clearances or denials) materially affect commercial access.
Clinical efficacy and safety: Clinical outcomes versus alternative carotid interventions (e.g., carotid endarterectomy and other stents) determine adoption.
Commercial execution: Scaling sales, convincing interventional physicians, and establishing hospital purchasing channels are challenging and time‑consuming.
Reimbursement and pricing: Securing favorable reimbursement for procedures using novel devices affects adoption and pricing power.
Financial and dilution risk: Small companies often raise capital, which can dilute existing shareholders and pressure the stock.
Liquidity and volatility: As a small‑cap stock, nspr stock can exhibit sharp price swings and low liquidity.

This list is not exhaustive; review company filings for additional risk disclosures and updates.

Legal and regulatory matters

Material lawsuits, regulatory investigations, or compliance issues are typically disclosed in annual and quarterly filings. As of 2026-01-27, there were no widely reported, singularly material litigation events disclosed in company filings that changed the collective risk profile beyond standard device‑related litigation exposure. For the latest status, consult the company’s SEC filings and legal footnotes.

References

Sources used to compile this article include company SEC filings and investor presentations, and market‑data pages such as Yahoo Finance, CNBC, Morningstar, Macrotrends, MarketChameleon, Robinhood profile summaries, StockTwits feeds and aggregated news pages. Specific referenced material is identified in disclosures and company press releases; readers should consult those primary documents for verification.

As of 2026-01-27, according to Yahoo Finance: market statistics and quote summary for NSPR.
As of 2026-01-27, according to CNBC and Morningstar: company profile and valuation indicators.
Historical price data and charts referenced from Macrotrends and market‑data aggregators for multi‑year performance context.
Clinical and regulatory milestone information from InspireMD press releases and conference abstracts (dates cited in those releases).

External links

InspireMD official investor relations and corporate website (see company communications for detailed filings and recent press releases).
Market quote pages (search for NSPR on major market‑data providers) for real‑time price and volume.